Last updated: 2026-09-07 05:18:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Enanta Pharmaceuticals, Inc. (ENTA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14,13, with a market capitalization of $410,38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7,05 to $17,15. This page covers its latest market performance, valuation, price trends and company information.
$410,38M | |
$14,29 | |
$127,77 | |
$4,09 | |
$14,02 | |
203,56K | |
-- | |
-- | |
$17,15 | |
$7,05 | |
-- | |
-- |
Enanta Pharmaceuticals, Inc. (ENTA) last closed at $14,02 as of 2026-09-04 23:31:00, unchanged from the previous close of $14,02.
During the latest regular trading session, ENTA traded between $4,09 and $127,77, with a volume of 203,56K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Enanta Pharmaceuticals, Inc. (ENTA) moved from $13,52 to $14,13, representing a gain of 4,48% ($0,61).
The stock traded between $13,56 and $14,34 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 237,79 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 70,1%
ENTA is currently trading at $14,13, placing it 70,1% of the way from its 52-week low of $7,05 to its 52-week high of $17,15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 120 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Enanta Pharmaceuticals, Inc. (ENTA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.